APGE
Apogee Therapeutics, Inc. Common Stock (APGE) Stock Valuation
Review Apogee Therapeutics, Inc. Common Stock (APGE) valuation with company data, supporting context and links to related investor research.
Research record updated: . Individual measures may refer to different reporting periods.
- Price to book
- 3.7
- BTI fair market cap
- $1.38B
- Premium or discount
- 505.74%
- Market cap
- $8.36B
Apogee Therapeutics, Inc. Common Stock (APGE) Stock Valuation research
The Apogee Therapeutics, Inc. Common Stock valuation page presents the available multiples, profitability measures and BTI fair-value context for APGE. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.
BTI fair value is a model estimate, not a quoted market price. The underlying assumptions and valuation date must be checked in the valuation tool before using the premium or discount. A missing multiple must not be interpreted as zero cost or zero risk.